Similar considerations can be entertained for patients receiving the third-generation EGFR TKI osimertinib, which has emerged as an attractive first-line treatment for NSCLC and for NSCLC harboring EGFR Thr790Met (T790M) mutations (29). This evidence concerns the gene EGFR and non-small cell lung carcinoma.